213 results
Page 2 of 11
8-K
EX-99.1
a7kkjex6alfk
24 Oct 23
Regulation FD Disclosure
4:30pm
8-K
EX-99.1
i0bmgtt22 8gob0t
15 Aug 23
Bio-path Holdings Reports Second Quarter 2023 Financial Results
7:10am
8-K
EX-99.1
4a883gqrr0gfgb tuy
7 Aug 23
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
4:42pm
424B3
h5lzk3l
7 Aug 23
Prospectus supplement
7:21am
424B4
rypr0limmw8du 58loa2
7 Aug 23
Prospectus supplement with pricing info
7:16am
8-K
EX-99.1
l67wr
1 Aug 23
Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia
5:02pm
8-K
EX-99.1
9zd6hgfn6xv7 amfb
17 Jul 23
Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
4:30pm
8-K
EX-99.1
ev8 o78a38a
12 May 23
Bio-path Holdings Reports First Quarter 2023 Financial Results
7:10am
8-K
EX-99.1
j8v796 g9
31 Mar 23
Bio-path Holdings Reports Full Year 2022 Financial Results
7:10am
8-K
EX-99.1
84dobihtj
7 Dec 22
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
4:30pm
8-K
EX-99.1
0q31dl6r62ym7t4 iw
15 Nov 22
Bio-path Holdings Reports Third Quarter 2022 Financial Results
7:30am